Table 1 Possible treatments directly targeting WAT and/or BAT in obesity and type 2 diabetes
From: Targeting adipose tissue
Drug | Effect | Mechanism of action | Target organ | Class |
|---|---|---|---|---|
BMP7 (OP-1TM) | BAT activation | Developmental regulator | BAT | Cytokine |
BMP8B | BAT activation | Developmental regulator | BAT, CNS | Â |
Sildenafil, vardenafil | WAT (trans-) differentiation, (BAT activation) | PDE5 inhibition | WAT, (BAT) | Enzyme inhibitor |
Amrinone | WAT lipolysis, (WAT transdifferentiation, BAT activation) | PDE3 inhibition | WAT, (BAT) | Â |
GC-1, KB-141 | BAT activation, (WAT transdifferentiation) | Thyroid hormone mimetics | BAT | Hormone |
T3 | BAT activation, (WAT transdifferentiation) | Thyroid hormone | BAT, CNS | Â |
BRL-26830, L-796568, N-5984 | BAT activation, WAT transdifferentiation, lipolysis | selective β3-AR agonist | BAT, WAT | Receptor agonist |
Bile acids (endogenous ligands) | BAT activation | TGR5 receptor agonist | BAT | Â |
ANP, BNP (endogenous ligands) | BAT activation, WAT transdifferentiation | NPRA agonsit | BAT, WAT | Â |
Rimonabant | WAT transdifferentiation | CB1 antagonist | WAT, CNS | Receptor antagonist |
TZDs, NS-1, balaglitazone, MRL-24, (Sulfonylureas) | WAT (trans-) differentiation, BAT activation | (partial) activation of PPARγ | WAT, BAT | Transcription factor ligand |